{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:42:18Z","timestamp":1791175338561,"version":"4.1.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:00:00Z","timestamp":1426636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0120561","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T20:30:56Z","timestamp":1426710656000},"page":"e0120561","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models"],"prefix":"10.1371","volume":"10","author":[{"given":"Sofia H. L.","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani L.","family":"Frayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnnie J.","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett C.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Hylarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom A.","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell R.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,18]]},"reference":[{"key":"ref1","article-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"J Ferlay","year":"2013"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"MS Kaminski","year":"2000","journal-title":"Blood"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"TE Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"DM Goldenberg","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/cbr.2010.0759","article-title":"Pretargeted radioimmunotherapy for hematologic and other malignancies","volume":"25","author":"RB Walter","year":"2010","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1073\/pnas.97.4.1802","article-title":"Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity","volume":"97","author":"DB Axworthy","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"G Paganelli","year":"1999","journal-title":"European journal of nuclear medicine"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V98.8.2535","article-title":"A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts","volume":"98","author":"OW Press","year":"2001","journal-title":"Blood"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2002-03-0874","article-title":"Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas","volume":"101","author":"JM Pagel","year":"2003","journal-title":"Blood"},{"issue":"3","key":"ref10","first-page":"437","article-title":"Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts","volume":"44","author":"K Subbiah","year":"2003","journal-title":"J Nucl Med"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2005-11-4327","article-title":"Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas","volume":"108","author":"JM Pagel","year":"2006","journal-title":"Blood"},{"issue":"20","key":"ref12","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1182\/blood-2008-11-187401","article-title":"A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations","volume":"113","author":"JM Pagel","year":"2009","journal-title":"Blood"},{"issue":"17","key":"ref13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"OW Press","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"OW Press","year":"2000","journal-title":"Blood"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"AK Gopal","year":"2003","journal-title":"Blood"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nucmedbio.2003.08.004","article-title":"Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice","volume":"31","author":"MR Lewis","year":"2004","journal-title":"Nucl Med Biol"},{"issue":"5","key":"ref17","first-page":"807","article-title":"Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production","volume":"47","author":"H Uusij\u00e4rvi","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1021\/bc200258x","article-title":"Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu","volume":"22","author":"H Mohsin","year":"2011","journal-title":"Bioconjugate chemistry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"701704","DOI":"10.1155\/2012\/701704","article-title":"Murine models of B-cell lymphomas: promising tools for designing cancer therapies","volume":"2012","author":"S Donnou","year":"2012","journal-title":"Advances in hematology"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000149930","article-title":"An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection","volume":"5","author":"G Klein","year":"1975","journal-title":"Intervirology"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2400555","article-title":"Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519)","volume":"11","author":"DM Jadayel","year":"1997","journal-title":"Leukemia"},{"key":"ref22","unstructured":"Axworthy DB, Theodore LJ, Gustavson LM, Reno JM, inventors; NeoRx Corporation (Seattle, WA) assignee. Biotinidase resistant biotin-DOTA conjugates. US patent 5 955 605. September 21, 1999."},{"issue":"3 Suppl","key":"ref23","first-page":"951","article-title":"A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates","volume":"73","author":"TE Hui","year":"1994","journal-title":"Cancer"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/cbr.2005.20.436","article-title":"Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides","volume":"20","author":"WH Miller","year":"2005","journal-title":"Cancer biotherapy & radiopharmaceuticals"},{"issue":"0","key":"ref25","article-title":"The iQID Camera: An ionizing-Radiation Quantum Imaging Detector","author":"BW Miller","year":"2014","journal-title":"Nuclear Instruments and Methods in Physics Research A"},{"issue":"11","key":"ref26","first-page":"2889","article-title":"Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate","volume":"51","author":"J Schlom","year":"1991","journal-title":"Cancer Res"},{"issue":"12","key":"ref27","first-page":"1447","article-title":"Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma","volume":"1","author":"T Mulligan","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref28","first-page":"1491","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49","volume":"37","author":"RF Meredith","year":"1996","journal-title":"J Nucl Med"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I\/II study","volume":"65","author":"RD Alvarez","year":"1997","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"ref30","first-page":"967","article-title":"Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I","volume":"42","author":"R Stein","year":"2001","journal-title":"J Nucl Med"},{"issue":"8","key":"ref31","first-page":"1310","article-title":"Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC","volume":"46","author":"F Forrer","year":"2005","journal-title":"J Nucl Med"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","article-title":"[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts","volume":"67","author":"M Persson","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-010-1639-2","article-title":"Lu-177-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to Bi-213-immunotherapy, but causes toxicity not observed with Bi-213","volume":"38","author":"C Seidl","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/028418601750444141","article-title":"Low-energy electron emitters for targeted radiotherapy of small tumours","volume":"40","author":"P Bernhardt","year":"2001","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I\/II study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","volume":"54","author":"F Forrer","year":"2013","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"ref36","first-page":"354","article-title":"A universal pretargeting system for cancer detection and therapy using bispecific antibody","volume":"63","author":"RM Sharkey","year":"2003","journal-title":"Cancer Res"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.2967\/jnumed.110.079376","article-title":"Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen\u2014expressing human colonic tumors in mice","volume":"51","author":"R Schoffelen","year":"2010","journal-title":"Journal of Nuclear Medicine"},{"issue":"22","key":"ref38","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1158\/1078-0432.CCR-05-0607","article-title":"Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein","volume":"11","author":"DJ Buchsbaum","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref39","first-page":"592","article-title":"Report No. 58: A Handbook of radioactivity measurements procedures","volume":"xvi","year":"1985"},{"issue":"1","key":"ref40","first-page":"75","article-title":"Nonuniformity of tumor dose in radioimmunotherapy","volume":"31","author":"JL Humm","year":"1990","journal-title":"J Nucl Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0120561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:31:44Z","timestamp":1598833904000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0120561"}},"subtitle":[],"editor":[{"given":"Farhat","family":"Afrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,18]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0120561","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,18]]}}}